396 related articles for article (PubMed ID: 29709670)
1. Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease.
Yun JH; Lamb A; Chase R; Singh D; Parker MM; Saferali A; Vestbo J; Tal-Singer R; Castaldi PJ; Silverman EK; Hersh CP;
J Allergy Clin Immunol; 2018 Jun; 141(6):2037-2047.e10. PubMed ID: 29709670
[TBL] [Abstract][Full Text] [Related]
2. Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort.
Hastie AT; Martinez FJ; Curtis JL; Doerschuk CM; Hansel NN; Christenson S; Putcha N; Ortega VE; Li X; Barr RG; Carretta EE; Couper DJ; Cooper CB; Hoffman EA; Kanner RE; Kleerup E; O'Neal WK; Paine R; Peters SP; Alexis NE; Woodruff PG; Han MK; Meyers DA; Bleecker ER;
Lancet Respir Med; 2017 Dec; 5(12):956-967. PubMed ID: 29146301
[TBL] [Abstract][Full Text] [Related]
3. Relationship of Blood Eosinophil Count to Exacerbations in Chronic Obstructive Pulmonary Disease.
Zeiger RS; Tran TN; Butler RK; Schatz M; Li Q; Khatry DB; Martin U; Kawatkar AA; Chen W
J Allergy Clin Immunol Pract; 2018; 6(3):944-954.e5. PubMed ID: 29153881
[TBL] [Abstract][Full Text] [Related]
4. Blood eosinophils as a biomarker of future COPD exacerbation risk: pooled data from 11 clinical trials.
Singh D; Wedzicha JA; Siddiqui S; de la Hoz A; Xue W; Magnussen H; Miravitlles M; Chalmers JD; Calverley PMA
Respir Res; 2020 Sep; 21(1):240. PubMed ID: 32943047
[TBL] [Abstract][Full Text] [Related]
5. Blood eosinophil count, a marker of inhaled corticosteroid effectiveness in preventing COPD exacerbations in post-hoc RCT and observational studies: systematic review and meta-analysis.
Harries TH; Rowland V; Corrigan CJ; Marshall IJ; McDonnell L; Prasad V; Schofield P; Armstrong D; White P
Respir Res; 2020 Jan; 21(1):3. PubMed ID: 31900184
[TBL] [Abstract][Full Text] [Related]
6. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial.
Watz H; Tetzlaff K; Wouters EF; Kirsten A; Magnussen H; Rodriguez-Roisin R; Vogelmeier C; Fabbri LM; Chanez P; Dahl R; Disse B; Finnigan H; Calverley PM
Lancet Respir Med; 2016 May; 4(5):390-8. PubMed ID: 27066739
[TBL] [Abstract][Full Text] [Related]
7. The association between eosinophilic exacerbation and eosinophilic levels in stable COPD.
Kang HS; Kim SK; Kim YH; Kim JW; Lee SH; Yoon HK; Rhee CK
BMC Pulm Med; 2021 Mar; 21(1):74. PubMed ID: 33653314
[TBL] [Abstract][Full Text] [Related]
8. Exacerbations and health care resource use among patients with COPD in relation to blood eosinophil counts.
Müllerová H; Hahn B; Simard EP; Mu G; Hatipoğlu U
Int J Chron Obstruct Pulmon Dis; 2019; 14():683-692. PubMed ID: 30962682
[TBL] [Abstract][Full Text] [Related]
9. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial.
Pascoe S; Barnes N; Brusselle G; Compton C; Criner GJ; Dransfield MT; Halpin DMG; Han MK; Hartley B; Lange P; Lettis S; Lipson DA; Lomas DA; Martinez FJ; Papi A; Roche N; van der Valk RJP; Wise R; Singh D
Lancet Respir Med; 2019 Sep; 7(9):745-756. PubMed ID: 31281061
[TBL] [Abstract][Full Text] [Related]
10. Stability of blood eosinophils in acute exacerbation of chronic obstructive pulmonary disease and its relationship to clinical outcomes: a prospective cohort study.
Cui Y; Zhang W; Ma Y; Zhan Z; Chen Y
Respir Res; 2021 Nov; 22(1):301. PubMed ID: 34819051
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of exacerbations and blood eosinophils in UK and US COPD populations.
Vogelmeier CF; Kostikas K; Fang J; Tian H; Jones B; Morgan CL; Fogel R; Gutzwiller FS; Cao H
Respir Res; 2019 Aug; 20(1):178. PubMed ID: 31391053
[TBL] [Abstract][Full Text] [Related]
12. Anti-IL-5 therapies for chronic obstructive pulmonary disease.
Donovan T; Milan SJ; Wang R; Banchoff E; Bradley P; Crossingham I
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013432. PubMed ID: 33295032
[TBL] [Abstract][Full Text] [Related]
13. Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies.
Criner GJ; Celli BR; Singh D; Agusti A; Papi A; Jison M; Makulova N; Shih VH; Brooks L; Barker P; Martin UJ; Newbold P
Lancet Respir Med; 2020 Feb; 8(2):158-170. PubMed ID: 31575508
[TBL] [Abstract][Full Text] [Related]
14. Benefits and Risks of Inhaled Corticosteroid Treatment in Patients with Chronic Obstructive Pulmonary Disease Classified by Blood Eosinophil Counts.
Saito Z; Yoshida M; Kojima A; Tamura K; Hasegawa T; Kuwano K
Lung; 2020 Dec; 198(6):925-931. PubMed ID: 33068153
[TBL] [Abstract][Full Text] [Related]
15. Eosinophil counts in first COPD hospitalizations: a comparison of health service utilization.
Bélanger M; Couillard S; Courteau J; Larivée P; Poder TG; Carrier N; Girard K; Vézina FA; Vanasse A
Int J Chron Obstruct Pulmon Dis; 2018; 13():3045-3054. PubMed ID: 30319252
[TBL] [Abstract][Full Text] [Related]
16. Blood Eosinophil Counts, Withdrawal of Inhaled Corticosteroids and Risk of COPD Exacerbations and Mortality in the Clinical Practice Research Datalink (CPRD).
Oshagbemi OA; Franssen FME; van Kraaij S; Braeken DCW; Wouters EFM; Maitland-van der Zee AH; Driessen JHM; de Vries F
COPD; 2019 Apr; 16(2):152-159. PubMed ID: 31117850
[TBL] [Abstract][Full Text] [Related]
17. Clinical implications of blood eosinophil count in patients with non-asthma-COPD overlap syndrome COPD.
Song JH; Lee CH; Kim JW; Lee WY; Jung JY; Park JH; Jung KS; Yoo KH; Park YB; Kim DK
Int J Chron Obstruct Pulmon Dis; 2017; 12():2455-2464. PubMed ID: 28860740
[TBL] [Abstract][Full Text] [Related]
18. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials.
Pascoe S; Locantore N; Dransfield MT; Barnes NC; Pavord ID
Lancet Respir Med; 2015 Jun; 3(6):435-42. PubMed ID: 25878028
[TBL] [Abstract][Full Text] [Related]
19. Absolute Blood Eosinophil Counts to Guide Inhaled Corticosteroids Therapy Among Patients with COPD: Systematic Review and Meta-analysis.
Oshagbemi OA; Odiba JO; Daniel A; Yunusa I
Curr Drug Targets; 2019; 20(16):1670-1679. PubMed ID: 31393244
[TBL] [Abstract][Full Text] [Related]
20. High eosinophil blood counts are associated with a shorter length of hospital stay in exacerbated COPD patients - a retrospective analysis.
Greulich T; Tüffers J; Mager S; Eder A; Maxheim M; Alter P; Schmeck B; Vogelmeier CF
Respir Res; 2020 May; 21(1):106. PubMed ID: 32375777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
